hepatic glycogen phosphorylase inhibitors (Novo Nordisk)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namehepatic glycogen phosphorylase inhibitors (Novo Nordisk)
Drug Alias NameDAB (Novo Nordisk)1,4-Dideoxy-1,4-imino-D-arabinitolType 2 diabetes therapeutics (Novo Nordisk)1,4-dideoxy-1,4-imino-D-arabinitolDAB
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen phosphorylase inhibitors
TargetsGlycogen phosphorylase
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A